HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impairment of synaptic vesicle exocytosis and recycling during neuromuscular weakness produced in mice by 2,4-dithiobiuret.

Abstract
Chronic treatment of rodents with 2,4-dithiobiuret (DTB) induces a neuromuscular syndrome of flaccid muscle weakness that mimics signs seen in several human neuromuscular disorders such as congenital myasthenic syndromes, botulism, and neuroaxonal dystrophy. DTB-induced muscle weakness results from a reduction of acetylcholine (ACh) release by mechanisms that are not yet clear. The objective of this study was to determine if altered release of ACh during DTB-induced muscle weakness was due to impairments of synaptic vesicle exocytosis, endocytosis, or internal vesicular processing. We examined motor nerve terminals in the triangularis sterni muscles of DTB-treated mice at the onset of muscle weakness. Uptake of FM1-43, a fluorescent marker for endocytosis, was reduced to approximately 60% of normal after either high-frequency nerve stimulation or K(+) depolarization. Terminals ranged from those with nearly normal fluorescence ("bright terminals") to terminals that were poorly labeled ("dim terminals"). Ultrastructurally, the number of synaptic vesicles that were labeled with horseradish peroxidase (HRP) was also reduced by DTB to approximately 60%; labeling among terminals was similarly variable. A subset of DTB-treated terminals having abnormal tubulovesicular profiles in their centers did not respond to stimulation with increased uptake of HRP and may correspond to dim terminals. Two findings suggest that posttetanic "slow endocytosis" remained qualitatively normal: the rate of this type of endocytosis as measured with FM1-43 did not differ from normal, and HRP was observed in organelles associated with this pathway- coated vesicles, cisternae, as well as synaptic vesicles but not in the tubulovesicular profiles. In DTB-treated bright terminals, end-plate potential (EPP) amplitudes were decreased, and synaptic depression in response to 15-Hz stimulation was increased compared with those of untreated mice; in dim terminals, EPPs were not observed during block with D-tubocurarine. Nerve-stimulation-induced unloading of FM1-43 was slower and less complete than normal in bright terminals, did not occur in dim terminals, and was not enhanced by alpha-latrotoxin. Collectively, these results indicate that the size of the recycling vesicle pool is reduced in nerve terminals during DTB-induced muscle weakness. The mechanisms by which this reduction occurs are not certain, but accumulated evidence suggests that they may include defects in either or both exocytosis and internal vesicular processing.
AuthorsYou-Fen Xu, Dawn Autio, Mary B Rheuben, William D Atchison
JournalJournal of neurophysiology (J Neurophysiol) Vol. 88 Issue 6 Pg. 3243-58 (Dec 2002) ISSN: 0022-3077 [Print] United States
PMID12466444 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • FM1 43
  • Fluorescent Dyes
  • Pyridinium Compounds
  • Quaternary Ammonium Compounds
  • Spider Venoms
  • alpha-latrotoxin
  • Horseradish Peroxidase
  • Thiourea
  • 2,4-dithiobiuret
Topics
  • Animals
  • Exocytosis (physiology)
  • Fluorescent Dyes
  • Horseradish Peroxidase (metabolism, pharmacokinetics)
  • Male
  • Mice
  • Mice, Inbred ICR
  • Nerve Endings (drug effects, metabolism, ultrastructure)
  • Neuromuscular Junction (drug effects, physiology)
  • Oxidation-Reduction (drug effects)
  • Pyridinium Compounds
  • Quaternary Ammonium Compounds
  • Spider Venoms (pharmacology)
  • Staining and Labeling
  • Synaptic Transmission (drug effects)
  • Synaptic Vesicles (physiology)
  • Thiourea (analogs & derivatives, pharmacology)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: